The role of tumour marker CA 125 in the treatment of ovarian cancer;Tumormarkøren CA 125's rolle i behandling af ovariecancer

Ugeskrift for Laeger

Volumn 160, Issue 7, 1998, Pages 995-1000

  Porsbjerg, Celeste M ^a   Sørensen, Jens Benn ^a   Lund, Birthe A ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

FEMALE; HUMAN; IMMUNOLOGY; OVARY TUMOR; PROGNOSIS; REVIEW; TUMOR RECURRENCE;

CA-125 ANTIGEN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032498405     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Nih Consensus Development Panel On Ovarian Cancer. Ovarian cancer screening, treatment and follow up. JAMA 1995; 273; 491-7.
2. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68: 1331-7.
3. Bast RC, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309 883-7.
4. Zurawski VR, Broderick SF, Pickens P. Serum CA 125 levels in a group of non hospitalized women. Relevance for early detection of ovarian cancer. Obstet Gynecol 1987, 69, 606
5. Ward BG. Tumor markers in ovarian cancer the current state in clinical use. Clin Lab Med 1994; 40: 1227-31.
6. Tuxen MK. Sölétormos G, Dombernowsky P. Tumormarkers in the management of patients with ovarian cancer. Cancer Treat Rev 1995; 21: 215-45
7. Grover S, Quinn AM, Weideman RN, Hoon K Factors influenzing serum CA 125 level in normal women. Obstet Gynecol 1992;79: 511-4.
8. Haga Y, Sakamoto K, Egami H, Yoshimura R, Akagi M. Evaluation of CA 125 levels in healthy individuals and pregnant women. Am J Med Sci 1986; 292: 25.
9. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium and endocervix. Am J Obstet Gynecol 1984; 148: 1057.
10. Haga Y, Sakamoto K, Egami H, Yoshimura R, Mon K, Akagi M. Clinical significance of serum CA 125 values in patients with cancers of the digestive system. Am J Med Sci 1986; 292: 30.
11. Pittaway DE, Fayez JA. The use of CA125 in the diagnosis and management of endometriosis. Fertil Steril 1986; 46: 790-5.
12. Halila H, Stenman UH, Seppölö M. Ovarian cancer antigen CA 125 in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327.
13. Takahashi K, Kijima S, Yoshino K, Schibukawa T, Kitao M. Serum CA 125 as a marker for patients with external endometriosis. Int J Fertil 1989; 34: 143.
14. Duk JM, Kauer FM, Fleuren GJ, De Bruijn HW. Serum CA 125 in patients with provisional diagnosis of pelvic inflammatory disease. Acta Obstet Gynecol Scand 1989; 68: 637-41.
15. Ruibal A, Encabo G, Martinez Mirailles E, Murcia C, Capdevilla JA, Salgado A et al. CA 125 seric levels in non ovarian pathologies. Bull Cancer (Paris) 1984; 71: 145-8.
16. Marechal F, Berthiot G, Deltour G Serum levels of CA 50, CA 19.9, CA 125, CA 5.3, enolase and CEA in non neoplastic diseases. Anticancer Res 1988; 8: 677-80.
17. Bergman JF, Beaugrand M, Labadie H, Bidart JM, Bohoun C.CA 125 in ascitic liver diseases. Clin Chim Acta 1986; 155: 163.
18. Bergman JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohoun C. Elevation of CA 125 in patients with benign and malign ascites. Cancer 1987; 59: 213-7.
19. Altaras MM. The role of cancer antigen 125 (CA125) in the management of ovarian epithelian carcinomas. Gynecol Oncol 1988; 30: 26-35.
20. Vergote IB, Børmer OP, Abeler VM. Evaluation of CA125 in the monitoring of ovarian cancer Am J Obstet Gynecol 1987; 157: 88-92.
21. Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996; 7: 361-4.
22. Kabawat SE, Bast RC, Bhan AK, Welch WR,Knapp Rc, Colvin RB. Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol 1983; 2: 275-85.
23. Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 1983; 49: 93-98.
24. Cruickshank DJ, Terry PB, Fullerton WT. CA125 response assessment in epithelial ovarian cancer Int J Cancer 1992; 51: 58-61.
25. Makar AP, Kristensen GB, Børmer OP, Tropé CG. Serum CA 125 levels allows early Identifikation of nonresponders during induction chemotherapy Gynecol Oncol 1993; 49: 73-9.
26. Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso V, Micelli G et al.Measurement of the ovarian cancer associated antigen CA 125 in monitoring tumor burden and response to chemotherapy. Tumori 1991; 77: 167-9.
27. Alvarez RD, To A Boots LR, Shingleton HM, Hatch KD, Hubbard J et al. CA 125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol 1987; 26: 284-9.
28. Bruzzone M, Onetto M, Campora E, Chiara S, Oliva C, Guido T et al. CA 125 monitoring in the management of ovarian cancer. Anticancer Res 1990; 10: 1353-60.
29. Brioschi PA, Rion O, Bischof P, Bader M, Forni M, Krauer F. Serum CA 125 in epithelial ovarian cancer. A longitud-inal study Br J Obstet Gynaecol 1987; 94: 196-201.
30. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC. CA 125 for the monitoring of ovarian carcinoma during primary therapy Obstet Gynecol 1987; 69: 223-8.
31. Mogensen O, Mogensen B, Jakobsen A, Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer Gynecol Oncol 1990; 37: 44-6.
32. Niloff JS, Bast RC, Schaetzl EM, Knapp RC. Predictive value of CA 125 antigen levels in second look procedures for ovarian cancer Am J Obstet Gynecol 1985; 151: 981.
33. Berek JS, Knapp RC, Malkasian GD. CA125 levels correlated with second look operations among ovarian cancer patients Obstet Gynecol 1986; 67: 685.
34. Atack DB, Nisker JA, Allen HH, Tustanof ER, Levin L. CA125 surveillance and second look laparotomy in ovarian cancer. Am J Obstet Gynecol 1986; 15: 287.
35. Rome RM, Koh H, Fortune D, Cauchi M. CA125 serum levels and secondary laparotomy in epithelial ovarian tumors. Aust NZ J Obstet Gynaecol 1987; 27: 142.
36. Rubin SC, Hoskins WJ, Hakes TB, Markman M, Reichman BS, Chapman D, et al. Serum CA125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989; 160: 667-71.
37. Hørding U, Toftager Larsen K, Lund B, Dreisler A, Daugaard S, Lundvall F et al. The value of CA125 measurement before second look laparotomy in patients with ovarian carcinoma. Eur J Gynaecol Oncol 199; 15: 217-21.
38. Mogensen O. Prognostic value of CA125 in advanced ovarian cancer Gynecol Oncol 1992, 44: 207-12.
39. Högberg T, Kågedal B. Serum half life of the tumor marker CA125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990; 69: 423-9.
40. Van der Burg MEL, Lammes FB, van Putten WLJ, Stoter G. Ovarian cancer the prognostic value of the serum half life of CA 125 during induction chemotherapy. Gynecol Oncol 1988; 30: 307-12.